Skip to main content
. 2022 Apr 29;22:68. doi: 10.1186/s12873-022-00631-7

Table 1.

Demographics and comorbidities – comparison between survivors and non-survivors

Total (n = 236) Survivors (n = 183) Non-Survivors (n = 53) p value
f (%) f (%) f (%)
Age (years)
 10–19 5 (2.12) 5 (2.73) 0 (0) 0.025
 20–29 21 (8.9) 20 (10.93) 1 (1.89) < 0.001
 30–39 27 (11.44) 25 (13.66) 2 (3.77) < 0.001
 40–49 43 (18.22) 37 (20.22) 6 (11.32) < 0.001
 50–59 50 (21.19) 43 (23.5) 7 (13.21) < 0.001
 60–69 49 (20.76) 32 (17.49) 17 (32.08) 0.032
 70–79 29 (12.29) 14 (7.65) 15 (28.3) 0.853
 80–89 9 (3.81) 6 (3.23) 3 (5.66) 0.317
 90–99 3 (1.27) 1 (0.55) 2 (3.77) 0.564
 Total 236 183 53
Gender
 Female 141 (59.75) 108 (59.02) 33 (62.26) < 0.001
 Male 95 (40.25) 75 (40.98) 20 (37.74) < 0.001
 Total 236 183 53
Race
 Black African 207 (87.71) 163 (89.07) 44 (83.02) < 0.001
 White 8 (3.39) 5 (2.73) 3 (5.66) 0.48
 Coloured 1 (0.42) 1 (0.55) 0 (0) 0.317
 Asian 20 (8.47) 14 (7.65) 6 (11.32) 0.074
 Total 236 183 53
Comorbidities
 Diabetes 79 (33.47) 58 (31.69) 21 (39.62) < 0.001
 Hypertension 95 (40.25) 59 (32.24) 36 (67.92) 0.018
 COPD/Asthma 12 (5.08) 9 (4.92) 3 (5.66) 0.083
 HIV 68 (28.81) 56 (30.6) 12 (22.64) < 0.001